Innovative Surgical Technology PROCEPT BioRobotics has developed the only AI-powered robotic system, HYDROS, for Aquablation therapy, offering a unique value proposition in the urology surgical market and enabling targeted sales efforts towards hospitals and clinics adopting advanced robotic solutions.

Strong Market Focus The company primarily targets treatment of benign prostatic hyperplasia, a condition affecting approximately 40 million men in the U.S., representing a significant patient base and a substantial revenue opportunity through direct sales and reimbursement partnerships.

Growing Clinical Evidence With over 150 peer-reviewed publications supporting Aquablation's benefits, PROCEPT has a solid clinical credibility that can be leveraged to persuade healthcare providers to adopt and incorporate their devices into standard practice.

Recent Leadership Expansion The appointment of a new CEO with experience in building successful medical device businesses indicates strategic growth and potential for accelerated market expansion, offering opportunities to partner with the company's leadership on sales initiatives.

Strategic Industry Presence Active participation in major industry events like the AUA Annual Meeting and the Piper Sandler Healthcare Conference provides high-visibility platforms to engage with key decision-makers, hospitals, and health systems for prospective sales collaborations.